Neuroendocrine Tumors of Pancreas — MCQs
Which of the following glands is NOT involved in Type I MEN?
Radiotherapy is most useful in:
Best way to localize extra-adrenal pheochromocytoma:
A 45-year-old gentleman has undergone truncal vagotomy and pyloroplasty for bleeding duodenal ulcer seven years ago. Now he has intractable recurrent symptoms of peptic ulcer. All of the following suggest the diagnosis of Zollinger-Ellison syndrome, except:
Marker for pancreatic non-functional neuro-endocrine tumor is
A 60-year-old male patient has an antral carcinoma spreading to the head of the pancreas with multiple small metastases to the right lobe of the liver. What is the best treatment approach?
What is the most specific marker for pancreatic acinar cell carcinoma?
The triad of diabetes, gallstones, and steatorrhea is associated with which of the following?
Middle segment pancreatectomy is avoided in which of the following conditions?
During Pylorus preserving pancreatico-duodenectomy (PPPD) the following organs are removed except:
Neuroendocrine Tumors of Pancreas Indian Medical PG Practice Questions and MCQs
Question 1: Which of the following glands is NOT involved in Type I MEN?
- A. Parathyroid
- B. Adrenal (Correct Answer)
- C. Pituitary
- D. Pancreas
Explanation: ***Adrenal*** - The **adrenal glands** are predominantly involved in **Multiple Endocrine Neoplasia type 2 (MEN2)**, particularly with pheochromocytomas, rather than MEN type 1. - While adrenal lesions (e.g., adenomas, hyperplasia) can occur sporadically or rarely in MEN1, they are not considered a primary or core component of the MEN1 syndrome as defined by the classic "3 Ps." [1] *Pancreas* - The **pancreas** is a primary gland involved in MEN1, frequently developing **neuroendocrine tumors** (e.g., gastrinomas, insulinomas). - These pancreatic tumors are a major cause of morbidity and mortality in MEN1 patients. *Pituitary* - The **pituitary gland** is one of the classic "3 P's" involved in MEN1, commonly developing **adenomas**, especially **prolactinomas**. [1] - These pituitary tumors can cause hormonal imbalances and mass effects within the sella turcica. *Parathyroid* - The **parathyroid glands** are almost universally involved in MEN1, with **hyperplasia** leading to **primary hyperparathyroidism**. [1] - This is often the earliest and most common clinical manifestation of MEN1.
Question 2: Radiotherapy is most useful in:
- A. Melanoma
- B. Pancreatic carcinoma
- C. Osteosarcoma
- D. Seminoma (Correct Answer)
Explanation: ***Seminoma*** - **Seminoma** is a highly **radiosensitive** tumor, making radiotherapy a cornerstone of its treatment, especially for localized disease and in adjuvant settings. - Due to its chemosensitivity and radiosensitivity, even advanced seminoma often responds well to treatment, leading to **high cure rates**. *Melanoma* - **Melanoma** is generally considered **radioresistant**, meaning that it does not respond well to conventional doses of radiation. - Treatment primarily involves **surgical excision**, immunotherapy, and targeted therapies. *Pancreatic carcinoma* - **Pancreatic carcinoma** is notoriously **radioresistant** and has a poor prognosis, with limited effectiveness of standalone radiation therapy. - Treatment often involves a combination of **surgery**, chemotherapy, and sometimes concurrent chemoradiation, though outcomes remain challenging. *Osteosarcoma* - **Osteosarcoma** is primarily managed with **surgical resection** and **neoadjuvant/adjuvant chemotherapy**, as it is relatively radioresistant. - Radiotherapy is typically reserved for unresectable tumors, palliative care, or when surgery is contraindicated.
Question 3: Best way to localize extra-adrenal pheochromocytoma:
- A. X-ray
- B. Clinical examination
- C. VMA excretion
- D. Nuclear medicine scan (MIBG scan) (Correct Answer)
Explanation: ***Nuclear medicine scan (MIBG scan)*** - **Iodine-131-metaiodobenzylguanidine (MIBG) scan** is the imaging modality of choice for localizing extra-adrenal pheochromocytomas due to its high specificity for **neuroendocrine tumors** like pheochromocytomas and paragangliomas. - MIBG is structurally similar to **norepinephrine** and is actively taken up by adrenergic neurons, allowing visualization of hypersecreting chromaffin cells wherever they are located in the body. *X-ray* - **X-rays** provide limited soft tissue detail and are generally not useful for localizing pheochromocytomas, especially extra-adrenal ones. - They may show calcifications in some tumors but lack the sensitivity and specificity needed for definitive localization. *Clinical examination* - A **clinical examination** can identify signs and symptoms suggestive of pheochromocytoma (e.g., hypertension, palpitations, sweating) but cannot localize the tumor itself. - Localization requires **imaging studies** due to the variable and often deep-seated location of these tumors. *VMA excretion* - **Vanillylmandelic acid (VMA) excretion** is a biochemical test used to diagnose pheochromocytoma by measuring catecholamine metabolites in urine. - While it confirms the presence of a catecholamine-secreting tumor, it provides **no information about the tumor's location**.
Question 4: A 45-year-old gentleman has undergone truncal vagotomy and pyloroplasty for bleeding duodenal ulcer seven years ago. Now he has intractable recurrent symptoms of peptic ulcer. All of the following suggest the diagnosis of Zollinger-Ellison syndrome, except:
- A. Ulcers in proximal jejunum and lower end of esophagus
- B. Basal acid output of 15 meq/hour
- C. Serum gastrin value of 500 pg/ml
- D. Serum gastrin value of 200 pg/ml with secretin stimulation (Correct Answer)
Explanation: ***Serum gastrin value of 200 pg/ml with secretin stimulation*** - A **positive secretin stimulation test** for Zollinger-Ellison syndrome (ZES) is indicated by a rise in serum gastrin of **≥ 200 pg/mL (or 110 pg/mL depending on the reference range)** above baseline after secretin administration. - A value of 200 pg/ml with secretin stimulation is not diagnostic if the baseline is not known or if the rise from baseline is not significant (i.e., less than 200 pg/ml absolute rise or less than 110 pg/ml rise depending on the specific criteria used). In the context of the other options, this relatively lower value is the *least* indicative of ZES. *Basal acid output of 15 meq/hour* - In a patient with prior vagotomy, a **basal acid output (BAO) of 15 meq/hour** is significantly elevated and highly suggestive of Zollinger-Ellison syndrome, as vagotomy aims to reduce acid secretion. - Normal BAO is typically < 5 mEq/hr, and a BAO > 15 mEq/hr (or > 6 mEq/hr in patients who have undergone prior acid-reducing surgery) is strongly indicative of excessive gastric acid production characteristic of ZES [1]. *Serum gastrin value of 500 pg/ml* - A **fasting serum gastrin level of 500 pg/ml** is markedly elevated (> 150-200 pg/mL is often considered suspicious), especially in the presence of recurrent ulcers, and is a strong indicator for Zollinger-Ellison syndrome [1]. - This value is well above the normal range (typically < 100 pg/ml) and falls into the range where gastrinoma should be highly suspected [1]. *Ulcers in proximal jejunum and lower end of esophagus* - The presence of **ulcers in unusual locations** such as the **proximal jejunum** is highly characteristic of Zollinger-Ellison syndrome due to the profound acid hypersecretion. - Esophageal ulcers, particularly at the lower end, are also common due to severe gastroesophageal reflux caused by high acid output overwhelming esophageal protective mechanisms.
Question 5: Marker for pancreatic non-functional neuro-endocrine tumor is
- A. CEA
- B. PSA
- C. CD100
- D. Chromogranin-A (Correct Answer)
Explanation: ***Chromogranin-A*** - **Chromogranin-A** is a glycoprotein found in the neurosecretory granules of various neuroendocrine cells, making it a reliable **general neuroendocrine tumor marker** [1]. - Elevated levels are particularly useful for detecting and monitoring **pancreatic non-functional neuroendocrine tumors**, which often lack specific hormonal symptoms. *CEA* - **Carcinoembryonic antigen (CEA)** is primarily used as a tumor marker for **colorectal cancer**, and less commonly for other adenocarcinomas like pancreatic adenocarcinoma. - It is generally **not a specific marker** for neuroendocrine tumors. *PSA* - **Prostate-specific antigen (PSA)** is a specific marker for **prostate cancer**, used for screening, diagnosis, and monitoring of this particular malignancy. - It has **no relevance** in the diagnosis or monitoring of pancreatic neuroendocrine tumors. *CD100* - **CD100** (also known as semaphorin-4D) is a membrane glycoprotein involved in immune cell regulation and has been implicated in certain cancers, such as those of **hematopoietic origin**. - It is **not used as a marker** for pancreatic non-functional neuroendocrine tumors. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Gastrointestinal Tract, pp. 780-781.
Question 6: A 60-year-old male patient has an antral carcinoma spreading to the head of the pancreas with multiple small metastases to the right lobe of the liver. What is the best treatment approach?
- A. Surgical resection with adjuvant chemotherapy
- B. Radiation therapy alone
- C. Palliative chemotherapy (Correct Answer)
- D. Supportive care only
Explanation: Palliative chemotherapy - The presence of **multiple small metastases** in the liver indicates **metastatic disease**, which is generally considered incurable with surgery [2]. - **Palliative chemotherapy** aims to control disease progression, alleviate symptoms, and improve quality of life in patients with advanced metastatic cancer. Surgical resection with adjuvant chemotherapy - **Surgical resection** is not indicated due to the presence of **distant metastases** (to the liver), classifying the disease as Stage IV [1]. - **Adjuvant chemotherapy** is given after curative surgery to reduce recurrence risk, which is not the goal here as the disease is already metastatic. Radiation therapy alone - **Radiation therapy alone** is typically reserved for localized disease or for palliative symptom management (e.g., pain from bone metastases), not for widespread metastatic disease. - It would not adequately address the systemic nature of **multiple liver metastases** from a pancreatic primary. Supportive care only - While supportive care is crucial, **palliative chemotherapy** offers a chance to prolong survival and manage symptoms more effectively than supportive care alone in suitable patients with advanced pancreatic cancer. - Skipping chemotherapy entirely would mean foregoing potential benefits in terms of disease control and quality of life, especially for patients with a good performance status.
Question 7: What is the most specific marker for pancreatic acinar cell carcinoma?
- A. Chromogranin
- B. Synaptophysin
- C. CK7
- D. Trypsin (Correct Answer)
Explanation: ***Trypsin*** - **Trypsin**, along with other pancreatic enzymes like lipase and alpha-1-antitrypsin, is a specific marker for **pancreatic acinar cell carcinoma** due to the tumor's characteristic differentiation towards acinar cells. - The detection of these enzymes in tumor tissue or serum can aid in the diagnosis and differentiation of this rare pancreatic malignancy. *Chromogranin* - **Chromogranin** is a marker for **neuroendocrine tumors**, not specifically acinar cell carcinoma. - While some pancreatic tumors can have neuroendocrine features, chromogranin is not the most specific marker for a pure acinar cell differentiation. *Synaptophysin* - **Synaptophysin** is another marker primarily associated with **neuroendocrine differentiation**. - Its presence indicates a neuroendocrine tumor rather than an acinar cell carcinoma, which derives from exocrine acinar cells. *CK7* - **CK7** (Cytokeratin 7) is a broad-spectrum **cytokeratin** often expressed in adenocarcinomas of various origins, including pancreatic ductal adenocarcinoma. - While pancreatic tumors can express CK7, it is not specific for acinar cell carcinoma and is more commonly associated with ductal differentiation.
Question 8: The triad of diabetes, gallstones, and steatorrhea is associated with which of the following?
- A. Somatostatinomas (Correct Answer)
- B. VIPomas
- C. Gastrinomas
- D. Glucagonomas
Explanation: ***Somatostatinomas*** - This **triad** is characteristic of a somatostatinoma, as somatostatin inhibits insulin release, gallbladder contraction, and pancreatic enzyme secretion. - The inhibition of **insulin release** leads to diabetes [1], blocked **cholecystokinin (CCK)** release causes gallstones, and reduced **pancreatic enzyme** secretion results in steatorrhea. *Gastrinomas* - Gastrinomas typically cause **Zollinger-Ellison syndrome**, characterized by severe peptic ulcers and diarrhea due to excessive acid production. - They are not directly associated with the specific triad of diabetes, gallstones, and steatorrhea. *VIPomas* - VIPomas are known for causing **Verner-Morrison syndrome** or pancreatic cholera, leading to severe watery diarrhea, hypokalemia, and achlorhydria. - Diabetes and gallstones are not prominent features of VIPomas. *Glucagonomas* - Glucagonomas primarily manifest with **diabetes** (due to elevated glucagon), a characteristic skin rash called **necrolytic migratory erythema**, and weight loss [1]. - While diabetes is present, gallstones and steatorrhea are not typical associations.
Question 9: Middle segment pancreatectomy is avoided in which of the following conditions?
- A. Tumors of head of pancreas
- B. Cystadenoma
- C. Tumors of tail of pancreas (Correct Answer)
- D. Tumor of neck of pancreas
Explanation: ***Tumors of tail of pancreas*** - Middle segment pancreatectomy involves resection of the central portion of the pancreas, usually sparing the head and tail. Therefore, it is not suitable for **tumors located in the pancreatic tail**. - For tail tumors, a **distal pancreatectomy** is the standard surgical approach, as it allows for complete resection of the tumor with appropriate margins. *Cystadenoma* - These are often located in the body or tail but can occur in the middle segment. If a **cystadenoma** is located in the middle segment, a middle segment pancreatectomy may be an appropriate treatment. - The decision to perform a middle segment pancreatectomy versus another procedure depends on the exact location and size of the cystadenoma, as well as its malignant potential. *Tumors of head of pancreas* - Tumors in the **head of the pancreas** typically involve crucial structures like the bile duct and duodenum. - For these tumors, a **pancreaticoduodenectomy (Whipple procedure)** is the standard and often only curative surgical option. *Tumor of neck of pancreas* - The **neck of the pancreas** is part of the middle segment of the pancreas. - Tumors in this location are amenable to **middle segment pancreatectomy**, as this procedure specifically targets resecting the central portion while preserving surrounding healthy tissue.
Question 10: During Pylorus preserving pancreatico-duodenectomy (PPPD) the following organs are removed except:
- A. Distal Bile Duct
- B. Gall bladder
- C. Stomach (Correct Answer)
- D. Head of pancreas
Explanation: ***Stomach*** - In a **pylorus-preserving pancreaticoduodenectomy (PPPD)**, the **pylorus** and a portion of the **stomach** are deliberately preserved. - This distinguishes it from the classic Whipple procedure, where the **antrum** and pylorus of the stomach are removed. *Distal Bile Duct* - The **distal bile duct** is routinely resected in both standard and pylorus-preserving Whipple procedures to ensure adequate margins and remove potential **lymph node** metastases. - This is necessary because pancreatic head tumors often involve or compress the **distal common bile duct**. *Gall bladder* - The **gallbladder** is invariably removed during a PPPD to provide access to the **common bile duct** and facilitate the creation of a **choledochojejunostomy**. - Its removal prevents future complications like **cholecystitis** or **choledocholithiasis** secondary to altered bile flow. *Head of pancreas* - The **head of the pancreas** is the primary target for resection in a PPPD as this is typically the location of the **tumor**. - This involves removing the mass along with surrounding pancreatic tissue to achieve clear **surgical margins**.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free